stockrow
Monday 9 November 2026
Export LRMR’s income statement to Excel — free account
Larimar Therapeutics, Inc.
LRMR- EPS
- +26.8%
- Free cash flow
- −127.6%
Quarter to June 2026, against a year earlier
2.39
0.07
+3.02%
Follow LRMR
Alert me
Larimar Therapeutics, Inc. (LRMR) P/E ratio
Larimar Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| FATE Fate Therapeutics, Inc. compare | n/m |
| LCTX Lineage Cell Therapeutics, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| ABEO Abeona Therapeutics Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| CAMP CAMP4 Therapeutics Corporation compare | n/m |
| LRMR Larimar Therapeutics, Inc. | n/m |
| QTTB Q32 Bio Inc. compare | 3.1× |
| CUVL Clinuvel Pharmaceuticals Ltd. - Sponsored ADR compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)